Dr. Reddy's Laboratories
Biosimilar developer, India. 5 development products across 5 molecules: bevacizumab, darbepoetin alfa, pegfilgrastim, rituximab, trastuzumab.
First approval in the Atlas: Mar 2010, Dr. Reddy's Laboratories (INN only), darbepoetin alfa (CDSCO)
FDAproducts approved1
EMAproducts approved1
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved4
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Bevacizumab | Dr. Reddy's bevacizumab | · | · | · | · | Sep 2018 | · |
| Darbepoetin alfa | Dr. Reddy's darbepoetin alfa | · | · | · | · | Mar 2010 | · |
| Pegfilgrastim | Dr. Reddy's pegfilgrastim | · | · | · | · | Jan 2011 | · |
| Rituximab | Zimrixby / Ituxredi DRL_RI | Jul 2026 | Sep 2024 | · | · | · | · |
| Trastuzumab | Dr. Reddy's trastuzumab | · | · | · | · | Mar 2018 | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- CDSCOMar 2010Dr. Reddy's Laboratories (INN only), darbepoetin alfa
- CDSCOJan 2011Dr. Reddy's Laboratories (INN only), pegfilgrastim
- CDSCOMar 2018Dr. Reddy's Laboratories (INN only), trastuzumab
- CDSCOSep 2018Dr. Reddy's Laboratories (INN only), bevacizumab
- EMASep 2024Ituxredi, rituximab
- FDAJul 2026Zimrixby, rituximab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.